Skin Cancer Research

Skin Cancer Research

Research into skin cancer at Penn State Cancer Institute is conducted by the melanoma and skin cancer team. See current clinical trials and members of that team here.

Clinical Trials

A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Prognosis of Recurrence Risk
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
The COVID-19 and Cancer Consortium (CCC19) Registry
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
Atypical Spotzoid Melanocytic Tumors: An Institutional Review of Outcomes for an Effective Treatment
Application for Discarded Tissue From Surgery For Research Use
Definition of Somatic Variants Corresponding to Immune Targets in Patients with Metastatic Melanoma
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer
Research into skin cancer at Penn State Cancer Institute is conducted by the melanoma and skin cancer team. See current clinical trials and members of that team here.
A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Prognosis of Recurrence Risk
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
The COVID-19 and Cancer Consortium (CCC19) Registry
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
Atypical Spotzoid Melanocytic Tumors: An Institutional Review of Outcomes for an Effective Treatment
Application for Discarded Tissue From Surgery For Research Use
Definition of Somatic Variants Corresponding to Immune Targets in Patients with Metastatic Melanoma
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)